Regentis Biomaterials Ltd(RGNT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 5 at 4:00 PM ET (Korea 11/6 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.45 | Insider Own | 31.06% | Shs Outstand | 4.9M | Perf Week | -13.97% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 4.8M | Perf Month | -28.22% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 15.86% | Short Float | 0.25% | Perf Quarter | -38.1% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | -2.66% | Short Ratio | 0.27 | Perf Half Y | -48.68% |
| Sales | 0.00B | P/B | 1.07 | EPS next 5Y | - | ROA | -265.04% | Short Interest | 0.01M | Perf YTD | -82.64% |
| Book/sh | 1.09 | P/C | 0.92 | EPS past 3/5Y | 11.45% -71.58% | ROE | - | 52W High | -92.45% ($15.50) | Perf Year | - |
| Cash/sh | 1.27 | P/FCF | - | Sales past 3/5Y | - | ROIC | -169.11% | 52W Low | -4.88% ($1.23) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -113.63% | Gross Margin | - | Volatility(W/M) | 9.76% 7.74% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.13 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.62 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 28.96 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.62 | Sales Q/Q | - | SMA20 | -17.21% ($1.41) | Beta | - | Target Price | $10 |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -31.7% ($1.71) | Rel Volume | 1.96 | Prev Close | $1.32 |
| Employees | 10 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -59.36% ($2.88) | Avg Volume(3M) | 0.05M | Price | $1.17 |
| IPO | 2025/12/4 | Option/Short | No/Yes | Trades | 105 | Volume | 90,267 | Change | -11.36% |
Regentis Biomaterials () is an Israel-based regenerative medicine company advancing cartilage regeneration through its Gelrin platform, which is built on a resorbable hydrogel implant. Its lead product, GelrinC, is a cell-free, off-the-shelf hydrogel designed to treat focal cartilage lesions in the knee. The product is administered via UV crosslinking, enabling the procedure to be completed in roughly 10 minutes. The company completed its listing on NYSE American in December 2025.
Over the past 1 year, on the lower side
92% below its 1-year high.
Traded more than usual. That is 196% of its average volume.
RGNT has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 15.9%.
Tap to view numbers
It ranks #50 of 51 in the industry
Based on market cap of $8M.
NXGL#47 Nexgel Inc $12M PER - 
FEMY#48 Femasys Inc $11M PER - 
CUPR#49 Cuprina Holdings (Cayman) Ltd $10M PER - RGNT#50 Regentis Biomaterials Ltd $8M PER - 
LUCY#51 Innovative Eyewear Inc $7M PER - 
FAQ
What kind of company is RGNT?
RGNT belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of RGNT?
The market cap of RGNT is approximately $8M, ranking 5,469 within its sector.
What is the 52-week high and low for RGNT?
RGNT has recorded a 52-week high of $15.50 and a low of $1.23.
